ISMICS Home  |  Past & Future Meetings
Countdown to ISMICS : 44 Days  
International Society For Minimally Invasive Cardiothoracic Surgery

Back to 2021 Cardiac Abstracts


Vascular Access Site Complications After Complete Percutaneous Transfemoral Transcatheter Aortic Valve Implantation
Jan Rychter1, Ryszard Leszek Walas1, Leszek Kukulski1, Michał Hawranek2, Mariusz Gąsior2, Tomasz Hrapkowicz1, Michał Oskar Zembala1.
1Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, 23rd Department of Cardiology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland.

BACKGROUND:
Aim of the study was to compare vascular access site and bleeding complications according to Vascular Closure Device used to achive a complete percutaneous approach for transfemoral transcatheter aortic valve implantation in a real world, all comers registry.
METHODS:
Retrospective study. Data collected from large national TAVI registry, from one of the European countries. The analysis included 1817 patients treated with complete percutaneous transfemoral transcatheter aortic valve implantation in years 2013-2018. 510 patients were treated using Prostar Vascular Closure Device (Abbott Vascular, Santa Clara, California) and 1307 using Proglide Vascular Closure Device (Abbott Vascular, Santa Clara, California). We analysed and compared this two groups on the incidence of vascular and bleeding complications after TAVI. We use unified criteria developed by the Valve Academic Research Consortium (VARC-2) for endpoint assessment and reporting in TAVI trials.
RESULTS:
Vascular access site complications were reported in 195 (10,7%) of 1817 patients. The data analysis showed reduced probability of all vascular complications, major and minor vascular complications in Proglide Vascular Closure Device group. The incidence for overall bleeding complications, major and minor bleedings was significantly higher in the patient group treated with Prostar Vascular Closure Device group.
CONCLUSIONS:
Proglide Vascular Closure Device used for complete percutaneous transfemoral transcatheter aortic valve implantation compared to Prostar Vascular Closure Device is associated with significantly reduced rate of all kind vascular access site complications. Also overall, life threatening, major and minor bleeding complications was significantly lower in the patient group treated with Proglide Vascular Closure Device.


Back to 2021 Cardiac Abstracts
By using this site, you agree to our updated Privacy Policy.  Got it